These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15772871)

  • 1. Collecting unit cost data in multicentre studies. Creating comparable methods.
    Wordsworth S; Ludbrook A; Caskey F; Macleod A
    Eur J Health Econ; 2005 Mar; 6(1):38-44. PubMed ID: 15772871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentre study of haemodialysis costs.
    Parra Moncasi E; Arenas Jiménez MD; Alonso M; Martínez MF; Gámen Pardo A; Rebollo P; Ortega Montoliú T; Martínez Terrer T; Alvarez-Ude F;
    Nefrologia; 2011; 31(3):299-307. PubMed ID: 21629336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing costing results in across country economic evaluations: the use of technology specific purchasing power parities.
    Wordsworth S; Ludbrook A
    Health Econ; 2005 Jan; 14(1):93-9. PubMed ID: 15386663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost of dialysis in France].
    Benain JP; Faller B; Briat C; Jacquelinet C; Brami M; Aoustin M; Dubois JP; Rieu P; Behaghel C; Duru G
    Nephrol Ther; 2007 Jun; 3(3):96-106. PubMed ID: 17540311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost of renal dialysis in a UK setting--a multicentre study.
    Baboolal K; McEwan P; Sondhi S; Spiewanowski P; Wechowski J; Wilson K
    Nephrol Dial Transplant; 2008 Jun; 23(6):1982-9. PubMed ID: 18174268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Costs of dialysis in hospitalised patients with acute or chronic renal failure, according to area of treatment].
    Jeantet A; Piccoli GB; Pacitti A; Thea A; Maffei S; Malfi B; Gai M; Bermond F; Burdese M; Bechis F; Mezza E; Segoloni GP; Piccoli G
    G Ital Nefrol; 2002; 19(3):308-15. PubMed ID: 12195399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equivalence of two healthcare costing methods: bottom-up and top-down.
    Chapko MK; Liu CF; Perkins M; Li YF; Fortney JC; Maciejewski ML
    Health Econ; 2009 Oct; 18(10):1188-201. PubMed ID: 19097041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The costs of dialysis in Canada.
    Prichard SS
    Nephrol Dial Transplant; 1997; 12 Suppl 1():22-4. PubMed ID: 9075224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Less frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: a European multicentre cost study.
    Burnier M; Douchamps JA; Tanghe A; Demey J; Perrault L; Foster CE; Robbins S
    J Med Econ; 2009 Jun; 12(2):77-86. PubMed ID: 19450138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness analysis of treatment for end-stage renal disease].
    Asgeirsdóttir TL; Asmundsdóttir G; Heimisdóttir M; Jónsson E; Pálsson R
    Laeknabladid; 2009 Nov; 95(11):747-53. PubMed ID: 19996463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Elements of economic problems in the field of extra-renal dialysis].
    Marissal JP; Sailly JC
    Sante Publique; 2002 Jun; 14(2):107-19. PubMed ID: 12375517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of depression in Europe.
    Sobocki P; Jönsson B; Angst J; Rehnberg C
    J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The marginal cost of satellite versus in-center hemodialysis.
    Soroka SD; Kiberd BA; Jacobs P
    Hemodial Int; 2005 Apr; 9(2):196-201. PubMed ID: 16191069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
    Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
    Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of end-stage renal disease care in planned dialysis start and type of renal replacement therapy--a Spanish multicentre experience.
    Marrón B; Ortiz A; de Sequera P; Martín-Reyes G; de Arriba G; Lamas JM; Martínez Ocaña JC; Arrieta J; Martínez F;
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 2():ii51-5. PubMed ID: 16825262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodialysis cost in Tehran, Iran.
    Mahdavi-Mazdeh M; Zamani M; Zamyadi M; Rajolani H; Tajbakhsh K; Heidary Rouchi A; Aghighi M; Mahdavi A
    Hemodial Int; 2008 Oct; 12(4):492-8. PubMed ID: 19090872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of alternative staff time data collection methods on drug treatment service cost estimates.
    Zarkin GA; Dunlap LJ; Wedehase B; Cowell AJ
    Eval Program Plann; 2008 Nov; 31(4):427-35. PubMed ID: 18640722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the effectiveness and benefits of peritoneal dialysis and haemodialysis using Nigerian made PD fluids.
    Arogundade FA; Ishola DA; Sanusi AA; Akinsola A
    Afr J Med Med Sci; 2005 Sep; 34(3):227-33. PubMed ID: 16749353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost of hemodialysis in Iran.
    Arefzadeh A; Lessanpezeshki M; Seifi S
    Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):307-11. PubMed ID: 19237828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.